NCT03775031 is a NA clinical trial of Fractional Laser and Chemical Peel in Skin Cancer, sponsored by Massachusetts General Hospital.

Who is sponsoring NCT03775031?

NCT03775031 is sponsored by Massachusetts General Hospital.

What drugs are being tested in NCT03775031?

Interventions in NCT03775031: Fractional Laser and Chemical Peel.

What condition does NCT03775031 study?

NCT03775031 studies Skin Cancer.

Is NCT03775031 still recruiting?

NCT03775031 is currently status unknown. Last updated 22 October 2020.

Last reviewed 2020-10-22 · How we verify

NCT03775031

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Chemical Peels and Fractional Laser on IGF-1 Levels in Skin

Status unknown NA Last updated 22 October 2020

What this trial tests

NA trial testing Fractional Laser and Chemical Peel in Skin Cancer in 20 participants. Status unknown.

Timeline

1 December 2019

Primary endpoint
1 July 2021

1 July 2021

Quick facts

Lead sponsor	Massachusetts General Hospital
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	single group
Masking	none
Primary purpose	prevention
Enrollment	20
Start date	1 December 2019
Primary completion	1 July 2021
Estimated completion	1 July 2021
Sites	1 location across United States

Drugs / interventions tested

Fractional Laser and Chemical Peel

Conditions studied

Skin Cancer — all drugs for Skin Cancer →

Sponsor

Massachusetts General Hospital

Who can join

55 and older, any sex, with Skin Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the impact of fractional laser versus chemical peels on IGF-1 levels in skin.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Skin Cancer

Currently open trials in the same condition.

NCT07288073 — TIL Therapy in cSCC and MCC · Phase 2 · recruiting
NCT06926075 — Early Phase Study of KESONOTIDE™in Participants With Solid Tumours · Phase 1, PHASE2 · recruiting
NCT06932172 — Artificial Intelligent Decision Support for Skin Cancer Diagnostics in Primary Care · NA · recruiting
NCT07510061 — Title: ICARUS - Psycho-physiological Profiling of Low and High Heat-resilient Individuals · NA · recruiting
NCT07200544 — Meloxicam in Mohs Micrographic Surgery · Phase 4 · recruiting

Other Massachusetts General Hospital trials

Trials by the same sponsor.

NCT03585946 — Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis · withdrawn
NCT07214831 — A Feasibility and Acceptability Study of a Large Language Model-based Chatbot for Brief Alcohol Intervention Among Emerg · NA · not yet recruiting
NCT06686901 — A Randomized Controlled Trial of a Smartphone Delivered Treatment for Suicidal Thoughts and Behavior · NA · not yet recruiting
NCT05854212 — Behavioral Economics to Implement Nutrition Ranking in Food Pantries · NA · not yet recruiting
NCT07323446 — The MIND Study: The MGH/MIT Investigation of NAC on Dysregulation · EARLY_PHASE1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03775031 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Massachusetts General Hospital
Last refreshed: 22 October 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03775031.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing